Table 4.
Lymphocyte subsets for predicting therapy response to vedolizumab.
| Lymphocyte subsets | Samples | Participants | Definition of response | Predictive value | References |
|---|---|---|---|---|---|
| CD4+ memory T cells | Blood at baseline | 15 UC | Clinical remission | Patients who achieved remission presented higher concentration than those who were did not (median: 394.47 vs. 304.73 cells/ml, P = 0.02). | Gonzalez-Vivo et al. (35) |
| CD4+ memory T cells | Blood at baseline | 15 UC | Biochemical remission or endoscopic improvement | Patients who were in remission had higher concentration than those were not (median: 394.47 vs. 304.73 cells/ml, P = 0.02). |
Gonzalez-Vivo et al. (35) |
| CD4+ memory T cells | Blood at baseline | 15 UC | Sustained clinical remission | Patients who were in remission presented higher concentration compared with non-remitters (median: 394.47 vs. 327.66 cells/ml, P = 0.02). | Gonzalez-Vivo et al. (35) |
| Memory Th1 cells | Blood at baseline | 18 CD, 20 UC | Short-term clinical remission | Higher levels were associated with clinical remission both in the total IBD cohort (18.3% in remitters vs 12.3% in non-remitters, P = 0.02) and when CD and UC patients were separately analyzed (P <0.05). | Coletta et al. (34) |
| Memory Th1 cells | Blood at baseline | 18 CD, 20 UC | Long-term clinical remission | Higher levels were significantly associated with clinical remission (P = 0.008). | Coletta et al. (34) |
| Memory Th1 cells | Blood at week 14 and baseline | 18 CD, 20 UC | Long-term clinical remission | Patients not achieving Week 54 clinical remission were characterized by a significantly higher increase compared with remitters (P < 0.01). | Coletta et al. (34) |
| Memory Th1/17 cells | Blood at baseline | 18 CD, 20 UC | Short-term clinical remission | Higher levels were associated with clinical remission both in the total IBD cohort [3.8% vs 1.0%, P = 0.012] and in CD patients [5.2% vs 1.5%, P = 0.026], but not in UC patients (P > 0.05). | Coletta et al. (34) |
| CD8+ α4β7+ memory T cells | Blood at baseline | 15 UC | Clinical remission | Patients who achieved remission presented higher concentration than those who did not (19.27 vs. 11.63 cells/ml, P = 0.02). | Gonzalez-Vivo et al. (35) |
| CD8+ α4β7+ memory T cells | Blood at baseline | 15 UC | Biochemical remission or endoscopic improvement | Patients who were in remission had higher concentration than those were not (median: 14.43 vs. 11.63 cells/ml, P = 0.02). |
Gonzalez-Vivo et al. (35) |
| CD8+ α4β7+ memory T cells | Blood at baseline | 15 UC | Sustained clinical remission | Patients who were in remission presented higher concentration compared with non-remitters (median: 14.43 vs. 11.85 cells/ml, P = 0.02). | Gonzalez-Vivo et al. (35) |
| α4β7+ T cells | Blood at baseline | 39 IBD | Clinical response | Cannot predict | Ungar et al. (32) |
| Memory Th17 cells | Biopsy at baseline | 18 CD, 20 UC | Endoscopic response | Reduced proportions were associated with endoscopic response in the total IBD cohort (P = 0.012) and in UC patients. | Coletta et al. (34) |
| Memory Th17 cells | Biopsy at baseline | 18 CD, 20 UC | Long-term clinical remission | Lower levels were significantly associated with clinical remission (P = 0.035). | Coletta et al. (34) |
| Memory Th1/17 cells | Biopsy at baseline | 18 CD, 20 UC | Endoscopic response | Reduced proportions were associated with endoscopic response in the total IBD cohort (P = 0.005) and in UC patients. | Coletta et al. (34) |
| Memory Th1/17 cells | Biopsy at baseline | 18 CD, 20 UC | Long-term clinical remission | Lower levels were significantly associated with clinical remission at Week 54 (P = 0.018). | Coletta et al. (34) |
| Effector memory CD4+ T cells | Biopsy at baseline | 11 CD, 20 UC | Endoscopic remission | A significant enrichment in non-remitters (P = 0.008). | Verstockt et al. (33) |
| Treg cells | Biopsy at baseline | 11 CD, 20 UC | Endoscopic remission | A significant enrichment in non-remitters (P = 0.05). | Verstockt et al. (33) |
| Naïve B cells | Biopsy at baseline | 11 CD, 20 UC | Endoscopic remission | A significant enrichment in remitters (P = 0.03). | Verstockt et al. (33) |
| GIMATS (IgG plasma cells, inflammatory mononuclear phagocytes, activated T cells, and stromal cells) | Biopsy at baseline | 84 IBD | Endoscopic response | Microarray dataset: AUC:0.661 (95% CI, 0.395-0.927) RNA-seq dataset: AUC =0.728 (0.583-0.873). |
Shi et al. (19) |
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; IQR, interquartile range; Treg cell, regulatory T cell.